NeuroPace (NASDAQ:NPCE) Issues Earnings Results, Beats Expectations By $0.07 EPS

NeuroPace (NASDAQ:NPCE) announced its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07, Zacks reports. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%.

NeuroPace Price Performance

NPCE traded up $0.11 during trading on Tuesday, reaching $11.92. 245,547 shares of the stock were exchanged, compared to its average volume of 119,388. NeuroPace has a 1 year low of $5.45 and a 1 year high of $16.34. The company has a market capitalization of $355.79 million, a price-to-earnings ratio of -11.92 and a beta of 2.05. The business’s 50 day moving average price is $12.70 and its two-hundred day moving average price is $9.71. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. UBS Group started coverage on NeuroPace in a research note on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price target on the stock. JPMorgan Chase & Co. boosted their target price on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. Finally, Wells Fargo & Company upped their price target on shares of NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $14.80.

Insider Transactions at NeuroPace

In related news, insider Martha Morrell sold 78,334 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $13.72, for a total value of $1,074,742.48. Following the sale, the insider now owns 81,993 shares of the company’s stock, valued at approximately $1,124,943.96. This represents a 48.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ltd. Kck sold 5,270,845 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $9.40, for a total value of $49,545,943.00. The disclosure for this sale can be found here. Insiders sold 5,352,479 shares of company stock valued at $50,670,217 in the last 90 days. 22.20% of the stock is currently owned by insiders.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.